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IMPORTANCE In Duchennemuscular dystrophy (DMD), the reading frame of an out-of-frame
DMD deletion can be repaired by antisense oligonucleotide (AO)–mediated exon skipping.
This creates a shorter dystrophin protein, similar to those expressed in themilder Becker
muscular dystrophy (BMD). The skipping of some exons may bemore efficacious than others.
Patients with exon 44 or 45 skippable deletions (AOs in clinical development) have a less
predictable phenotype than those skippable for exon 51, a group in advanced clinical trials. A
way to predict the potential of AOs is the study of patients with BMDwho have deletions that
naturally mimic those that would be achieved by exon skipping.
OBJECTIVE To quantify dystrophin messenger RNA (mRNA) and protein expression in
patients with DMD deletions treatable by, or mimicking, exon 44 or 45 skipping.
DESIGN, SETTING, AND PARTICIPANTS Retrospective study of nondystrophic controls (n = 2),
patients with DMD (n = 5), patients with intermediate muscular dystrophy (n = 3), and
patients with BMD (n = 13) at 4 university-based academic centers and pediatric hospitals.
Biochemical analysis of existing muscle biopsies was correlated with the severity of the
skeletal muscle phenotype.
MAIN OUTCOMES ANDMEASURES DystrophinmRNA and protein expression.
RESULTS Patients with DMDwho have out-of-frame deletions skippable for exon 44 or 45
had an elevated number of revertant and trace dystrophin expression (approximately 19% of
control, using quantitative immunohistochemistry) with 4 of 9 patients presenting with an
intermediate muscular dystrophy phenotype (3 patients) or a BMD-like phenotype (1
patient). Corresponding in-frame deletions presented with predominantly mild BMD
phenotypes and lower dystrophin levels (approximately 42% of control) than patients with
BMDmodeling exon 51 skipping (approximately 80% of control). All 12 patients with in-frame
deletions had a stable transcript compared with 2 of 9 patients with out-of-frame deletions
(who had intermediate muscular dystrophy and BMD phenotypes).
CONCLUSIONS AND RELEVANCE Exon 44 or 45 skipping will likely yield lower levels of
dystrophin than exon 51 skipping, although the resulting protein is functional enough to often
maintain a mild BMD phenotype. Dystrophin transcript stability is an important indicator of
dystrophin expression, and transcript instability in DMD compared with BMD should be
explored as a potential biomarker of response to AOs. This study is beneficial for the planning,
execution, and analysis of clinical trials for exon 44 and 45 skipping.
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D uchenne muscular dystrophy (DMD) is caused byframe-disruptingmutations in theDMDgene thatpre-vent the full translation of its protein product,
dystrophin.1,2 Duchenne muscular dystrophy is character-
ized by progressive muscle weakness and degeneration re-
sulting in loss of ambulation at approximately 13 years of age
in the steroid-treated population3 anddeath from respiratory
and/or cardiac failure in the thirdor fourthdecadeof lifewhen
supportedbynoninvasiveventilation.4-6 In-frame (IF) dystro-
phinmutations thatdonotdisrupt theopenreading frametypi-
cally cause a clinicallymilder disorder, Beckermuscular dys-
trophy (BMD).7,8 The IFmutations result in the translation of
an internally deleted dystrophin protein; variations in the
amount and functionality of these different dystrophin pro-
teins contribute to thevariablephenotypic spectrumofBMD.9
Dystrophin is a large sarcolemmal protein that forms part
of the dystrophin-associated protein complex.10,11 Dystro-
phin protects muscle fibers against the mechanical forces of
contraction and plays a role in signaling; the loss of dystro-
phin leads to secondary sarcolemmal protein deficiencies.
Antisense oligonucleotide (AO)–mediated exon skipping
aims to restore theDMD reading frame toallow theproduction
of an internally deleted dystrophin protein and, hopefully, a
functional benefit to patients with DMD who have out-of-
frame (OOF) deletions.12-14 The restoration of dystrophin and
membersofthedystrophin-associatedproteincomplexhasbeen
achieved following local and systemic injectionsofAOs target-
ing exon 51.15-19 Efforts are now focused on targeting other
exons12,20; however, the skipping of some exonsmay bemore
efficacious thanothers.Topredict thepotentialofvariousexon
skippingstrategies,westudiedpatientswithBMDwhohavede-
letions that naturally mimic those achieved by exon skipping.
Wepreviouslyquantifieddystrophin inpatientswithBMD
who have IF deletions that mimic skipping of exons 51, 45
through 55, and 53.21 While these results proved encouraging
for exon 51 and 53 skipping, several factors should be consid-
eredwhendeveloping and assessing the efficacy of strategies
for skipping exons44 and45,which are among themost com-
monDMD skippable exons. First, the percentage of revertant
and trace dystrophin expression in patients with deletions
flankingexon44 is significantlyhigher thanwithdeletionssur-
rounding exon 51.22 Second, OOF deletions around exons 44
and 45 result in a variety of clinical severities including inter-
mediate muscular dystrophy (IMD) and BMD.23-27
Herein, we characterize patients with IF and OOF DMD
deletions around exons 44 and 45 to enhance the planning,
execution, and analysis of clinical trials for exon 44 or 45
skipping.
Methods
Twenty-one patients (Table 1) were retrospectively selected
from4centers: (1)UniversityCollegeLondon, InstituteofChild
Health and Great Ormond Street Hospital, London, England;
(2) Institute of GeneticMedicine, Newcastle University, New-
castle, England; (3) Institute of Neurology, Catholic Univer-
sity School ofMedicine, Rome, Italy; and (4)University of Fer-
rara, Ferrara, Italy. Research ethics committee approval was
obtained from the London–West LondonGeneTherapyAdvi-
soryCommittee.Local researchanddevelopmentapprovalwas
also obtained from Great Ormond Street Hospital and the In-
stitute of Child Health.
Selection criteria included an IForOOFDMDdeletion rel-
evant to exon 44 or 45 skipping28 (confirmed bymultiplex li-
gation-dependent probe amplification) and the availability of
a muscle biopsy. A standardized questionnaire was distrib-
uted to obtain information on geneticmutation, age at onset,
age at biopsy, motor function abilities at the latest assess-
ment, and other comorbidities.
Patients with BMDwere classified as asymptomatic, hav-
ing mild BMD, or having severe BMD according to the age at
onset, relevant history, and overall motor function through-
out the disease course. Asymptomatic individuals had no de-
tectable muscle weakness and the only pathological feature
wasanelevatedserumcreatinekinase level.MildBMDwasde-
fined as havingmild proximalmuscleweakness but retaining
runningabilitybeyondadolescence. Individualswhoeither lost
running ability by the end of adolescence or never ran were
classified as having severe BMD.
Skeletal muscle biopsies (14 quadriceps, 4 deltoid, and 3
unknown) were previously obtained with written informed
consent. Nondystrophin controlmuscle biopsies (n = 2, para-
spinal and intercostal muscles) were obtained from the MRC
Centre for Neuromuscular Diseases Biobank, London (http:
//www.cnmd.ac.uk). Biochemical analysis of all samples was
performed in London to minimize variability.
Quantitative immunohistochemistry was performed as
previously described.21 A 2-tailed unpaired t testwas used for
statisticalanalysis, andstatistical significancewassetatP = .05.
Westernblottingwasperformedaspreviouslydescribed.21
Dystrophin intensity was normalized to α-actinin using Im-
ageLaboratory software (BioRad) and expressed as a percent-
age of control.
Total RNA was extracted, DNase treated, reverse tran-
scribed, and subjected to quantitative polymerase chain reac-
tion as previously described.29 Three dystrophin TaqMan as-
says (AppliedBiosystems)wereusedwithprobes spanning the
junctionsof exons 19and20, 53and54, and73and74 (Table 2).
Starting concentrationswere calculatedusing the LinRegPCR
program.30,31 Data were normalized to myotilin and pre-
sentedrelative tocontrol.A2-wayanalysisofvarianceandBon-
ferroni posttest were used to determine statistical signifi-
cance.
Results
Westudied a total of 21 patients (Table 1). Of these, 9 hadOOF
deletions skippable by exon 44 or 45 (models 44 and 45 OOF)
and 12 had IF deletions mimicking the skipping of exon 45
(model 45 IF).
Clinical Characteristics
Four of 9 patients (44.4%) with OOF deletions had an IMD or
BMD phenotype. Patients 1 and 2 (both with IMD) were am-
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bulant at ages 15 and 14years, respectively, despitehavingdis-
continued steroids. Patients 3 (with IMD) and6 (withBMD)are
still ambulant at ages 17 and 37 years, respectively. All 12 pa-
tients with IF deletions had a BMD phenotype. Their average
ageat studywas9years (range, 3-33years) and theaverage age
at onset was 5 years (range, 1-9 years). Of the 12 patients with
IF deletions and BMD, 1 was asymptomatic, 8 hadmild BMD,
and3hadsevereBMD.Patient 14withasymptomaticBMDwas
diagnosed incidentally at age 3years andwasable to runwhen
last seenat theclinicatage14years.Patient 18withsevereBMD
presented at age 9 years and by age 14 years he could not run
and could only walk for a maximum of 10 minutes. Patients
17 and 19 with severe BMD had ages at onset of 5 and 3 years,
respectively; while both retaining ambulation into their late
teens, neither can run andpatient 17 requires awheelchair for
long distances.
Table 1. Summary of Clinical Features
Patient No.
Exon
Deletion
Exon
Skipping
Model Frame
Age at Biopsy,
y Age at Onset Phenotype Symptoms Motor Function
1 42-43 44 OOF 7 6 y IMD Unable to jump Walking indoors at
age 15 y
2 42-43 44 OOF 9 3 y IMD Motor delay Walking indoors at
age 14 y
3 45 44 OOF 8 Unknown IMD Toe walking Ambulant at age 17
y, not running,
difficulty climbing
stairs
4 45 44 OOF 3 2 y DMD Frequent falls LOA at age 11 y
5 45 44 OOF 1 17 mo DMD Delayed walking,
diagnosed by
incidental high
serum CK level
LOA at age 12 y
6 44 45 OOF 17 Teens BMD … Ambulant indoors
at age 37 y
7 44 45 OOF 5 2 y DMD Difficulty walking LOA at age 11 y
8 44 45 OOF 4 2 y DMD Delayed walking LOA at age 11 y
9 46-47 45 OOF 5 4 y DMD Frequent falls,
unable to jump
LOA at age 11 y
10 45-47 45 IF 8 5 y BMD (mild) Walking and
learning difficulties
Ambulant at age
20 y, difficulty
climbing stairs
11 45-47 45 IF 16 8 y BMD (mild) Difficulty walking Ambulant at age
33 y, difficulty
climbing stairs
12 45-47 45 IF Unknown Unknown BMD (mild) … Ambulant at age
13 y
13 45-47 45 IF 7 6 y BMD (mild) Enlarged calves Ambulant at age
9 y, swimming and
sporty
14 45-47 45 IF 3 3 y BMD (asymptomatic) Incidental finding Able to run at age
14 y, Gowers sign
negative
15 45-48 45 IF 6 5 y BMD (mild) Difficulty walking Able to run at age
19 y, plays
football
16 45-48 45 IF 33 8 y BMD (mild) Difficulty climbing
stairs
Ambulant at age
36 y
17 45-49 45 IF 7 5 y BMD (severe) Unable to jump, calf
hypertrophy
Ambulant at age
17 y, wheelchair for
long distances,
struggles to rise
from floor
18 45-49 45 IF 10 9 y BMD (severe) Calf hypertrophy,
motor difficulties
Ambulant for
maximum of 10 min
at age 14 y, wheel-
chair for long
distances
19 45-49 45 IF 3 3 y BMD (severe) Incidental finding,
severely autistic
Ambulant at age
14 y, unable to run
20 45-49 45 IF 5 5 y BMD (mild) Motor and learning
difficulties, behav-
ioral problems
Ambulant at age 15
y, able to run, plays
football
21 45-49 45 IF 6 1-2 y BMD (mild) Difficulty rising
from floor
Ambulant at age
21 y
Abbreviations: BMD, Becker muscular dystrophy; CK, creatine kinase; DMD,
Duchennemuscular dystrophy; IF, in-frame; IMD, intermediate muscular
dystrophy; LOA, loss of ambulation; OOF, out-of-frame; ellipses, unreported.
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Quantification of Dystrophin Protein and
Transcript Expression
Dystrophinprotein expressionwasquantifiedby immunohis-
tochemistryusingMANDYS106(exon43),MANEX50(exons49-
50), and Dys2 (last 17 C-terminal amino acids) antibodies.
Dystrophin levels in the model 44 OOF group had a
mean (SD) of approximately 20% (18.3%) of control for
MANDYS106, approximately 25% (14.4%) for MANEX50, and
approximately 16% (6.4%) for Dys2 (Figure 1A and eFigure 1
in Supplement). Patients in the model 45 OOF group had
comparable mean (SD) levels of approximately 18% (20.2%)
of control for MANDYS106, approximately 21% (24.3%) for
MANEX50, and approximately 22% (26.0%) for Dys2. Higher
levels of dystrophin expression were observed in the model
45 IF group, which had a mean (SD) of approximately 44%
(6.8%) of control for MANDYS106, approximately 41%
(8.8%) for MANEX50, and approximately 43% (9.2%) for
Dys2 (Figure 1A). Patients 1 and 2 lack the MANDYS106 epit-
ope and patients 17 through 21 lack the MANEX50 epitope;
these data points were excluded as they do not represent
dystrophin content.
Notable variability was observed between patients with
OOF and IF deletions (Figure 1A and eFigure 1 in Supple-
ment). Patients 3 (with IMD) and 6 (with BMD) had relatively
high dystrophin levels (approximately 41.0% and 48.4%, re-
spectively, forMANDYS106),while patients 4 and 5withDMD
had low levels of dystrophin expression (approximately 9.1%
and8.8%, respectively, forMANDYS106).Meandystrophin lev-
els for themodel 45 IF groupwere significantly higher than at
least 1 of the OOF groups with all 3 antibodies (Figure 1A).
We compared the mean level of dystrophin protein ex-
pression in the IF andOOFgroupsvspatientswith IF andOOF
deletions from our previous study on patients with deletions
relevant to exon 51 skipping (Figure 1A).21 The level of dystro-
phin in OOFmodels 44 and 45 was higher than with OOF de-
letionsskippable forexon51.Conversely, themodel45 IFgroup
had a lower dystrophin level (mean [SD], 44% [6.8%] for
MANDYS106and43%[9.2%] forDys2) than thatpreviously re-
ported for the IFmodel 51 group (mean [SD], 84% [15.8%] for
MANDYS106 and 79% [17.1%] for Dys2).
Wenext quantifieddystrophinprotein expression in6pa-
tients (patient 7 with DMD and patients 12, 14, 15, 16, and 20
withBMD)byWesternblotting (Figure 1B).Nodystrophinwas
detected for patient 7withDMD,while the patientswithBMD
had amean (SD) dystrophin protein expression of 17% (7.5%)
of control. In our previous study on patients with BMDmim-
icking exon 51 skipping, Western blotting revealed a dystro-
phin level of approximately 65% of control21 (Figure 1B), con-
firming thatdystrophinproteinexpression in this currentBMD
cohort is relatively low.
It has been suggested that it is the stability rather than the
amountof theDMD transcript thatdetermines the level ofdys-
trophinprotein and that there is a 5′ to 3′ imbalance in the sta-
bility of the dystrophin transcript.32-35 We quantified dystro-
phinmessengerRNA (mRNA) and investigated, indirectly, the
stabilityof thedystrophintranscriptusingTaqManassaysspan-
ning exon junctions 19 and 20, 53 and 54, and 73 and 74
(Figure 1C and eFigure 2 in Supplement). The relative expres-
sion of dystrophinmRNAusing a TaqMan assay for the 5′ end
of the transcript was similar to control in all 21 patients and
the level of dystrophin mRNA does not correlate to the level
of dystrophin protein (Figure 1, and eFigure 1 and eFigure 2
in Supplement). We observed a decrease in transcript levels
in some patients with the exon junction 53 and 54 assay (ie,
3′ to the deletion breakpoint) that was more pronounced in
patients with OOF deletions. Model 45 OOF and model 45 IF
group means were statistically different with the exon junc-
tion 73 and 74 probe (P = .03) (Figure 1C), with 7 of 9 patients
in the OOF group (patients 1, 2, 4, 5, 7, 8, and 9) showing a
clear DMD transcript instability (eFigure 2 in Supplement).
Interestingly, all these patients have been diagnosed as hav-
ing DMD or IMD and low dystrophin levels compared with
patients with a more stable dystrophin transcript. Patients 3
and 6 with IMD were the only 2 patients with OOF deletions
that retained a high level of DMDmRNA expression with the
exon junction 73 and 74 assay (mean [SD], approximately
1.35 [0.30] and 0.83 [0.08], respectively); these patients also
had the highest dystrophin protein levels among the OOF
cohort (mean [SD], approximately 40.6% [10.66%] and
48.4% [20.07%], respectively, with MANDYS106). Similarly,
all patients with BMD who have IF deletions retained a high
level of DMD mRNA with all 3 assays (mean [SD], approxi-
mately 1.09 [0.27] for the exon junction 19 and 20 assay,
approximately 1.16 [0.58] for the exon junction 53 and 54
assay, and approximately 1.10 [0.24] for the exon junction 73
and 74 assay) (Figure 1C).
Table 2. TaqMan Assay Sequences
Assay
Primer
Probe
Product
Length,
bp
Mean PCR
EfficiencyaForward Reverse
Dystrophin 19 (Exon 19)
TCAGGCCCTGGTGGAACA
(Exon 20)
CTGAGGCTTGTTTGATGCTATCTG
TGGTGAATGAGGGTGTTAA 65 1.81
Dystrophin 53 (Exon 53)
GTCCCTATACAGTAGATGCAATCCAA
(Exon 54) GCCACTGGCGGAGGTCTT CCAAGCAGTTGGCC 75 1.80
Dystrophin 73 (Exon 73) assay Hs01049401_m1b (Exon 74) assay Hs01049401_m1b Assay Hs01049401_m1b 105 1.90
Myotilin (Exon 4) assay Hs00199016m1b (Exon 5) assay Hs00199016m1b Assay Hs00199016m1b 57 1.86
Abbreviations: bp, base pairs; PCR, polymerase chain reaction.
a Representative mean experimental efficiencies used to calculate starting concentration, N0. All assays had efficiencies greater than 90%when determined using
the standard curvemethod on unlimited samples.
bApplied Biosystems catalog assay; exact sequences are unavailable.
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Quantification of Dystrophin-Associated Protein Expression
To assess the functional properties of the different dystro-
phin proteins expressed in our cohort, we quantified the ex-
pression of β-dystroglycan, neuronal nitric oxide synthase
(nNOS), and utrophin by quantitative immunohistochemis-
try (Figure 2 and eFigure 3 in Supplement).
Figure 1. Comparative Analysis of Dystrophin Protein and Transcript Expression in PatientsWith In-Frame or Out-of-FrameDMDDeletions Around
Exons 44 and 45
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A, Transverse muscle sections were immunolabeled for β-spectrin,
MANDYS106, MANEX50, and Dys2. Protein expression was quantified relative
to control muscle in 40muscle fibers and normalized to β-spectrin expression.
Patients were grouped according to corresponding exon skippingmodels for
Duchennemuscular dystrophy: control, exon 44 or 45 skippable out-of-frame
(OOF) deletions (model 44 OOF andmodel 45 OOF), and in-frame (IF)
deletions mimicking exon 45 skipping (model 45 IF). Data are presented as
mean (SD) of the difference between sample means. Dotted lines indicate the
mean dystrophin protein expression level from patients with Becker muscular
dystrophy who have IF (blue lines) and OOF (gray lines) deletions modeling
exon 51 skipping quantified in our previous study.21 B, Western blotting analysis
of patients 7, 12, 14, 15, 16, and 20. Data are normalized to α-actinin and
presented as themean (SD) percentage of control. Dotted line indicates the
mean dystrophin protein expression level from patients with Becker muscular
dystrophy who have IF deletions modelling exon 51 skipping quantified in our
previous study.21 C, The DMDmessenger RNA transcript levels were quantified
using 3 separate TaqMan assays (Applied Biosystems) targeting exon
boundaries 19 and 20, 53 and 54, and 73 and 74. Themean polymerase chain
reaction efficiency per amplicon (Table 2) and themean threshold cycle (Ct)
value per sample were used to calculate the starting concentration (N0) using
the equationN0 = Nt/ECtwhere Nt is the fluorescence threshold and E is the
efficiency. Data were normalized tomyotilin, and dystrophin transcript
expression is presented as mean (SD) relative to control.
aP = .002.
bP = .001.
cP = .03.
dP < .001.
eP = .02.
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The mean (SD) β-dystroglycan levels in the OOF and IF
groupswere lower thancontrol andhighly comparable (model
44OOF: approximately 41% [8.9%] of control;model 45OOF:
approximately 42% [12.0%] of control; and model 45 IF: ap-
proximately 43% [9.9%] of control). These levels appear un-
related to the level of dystrophin protein expression (Figure 1
and eFigure 1 in Supplement). β-Dystroglycan levels in pa-
tients with IF deletions were lower than those with IF dele-
tionsmimickingexon51skipping (Figure2), reflectingthe lower
level of dystrophin observed in this study; conversely, the
β-dystroglycan levels in the OOF groups were higher than in
patients with OOF deletions mimicking exon 51 skipping
(Figure 2).21
All but 1 (patient 9) of the 21 patients have incomplete
nNOS-binding domains (encoded by exons 42-45); conse-
quently, thesepatientshavevirtually absent levelsofnNOSex-
pression,with patient 9 having the highest level of 8.8%. Sar-
colemmal nNOS protein expression was significantly lower
with the model 45 IF group compared with both OOF groups
(Figure 2).
There is limited information on the levels of the dystro-
phinhomologutrophin inBMDor towhat extentutrophinand
dystrophin are present together at the sarcolemma.36-38 The
2OOFmodels hadhighmean (SD) levels of sarcolemmal utro-
phin expression (model 44OOF: approximately 501% [94.7%]
of control; and model 45 OOF: approximately 438% [235.1%]
of control). The model 45 IF group had a significantly lower
and less variable mean (SD) level of approximately 280%
(63.5%)of control,whichwashigher than inpatientswithBMD
modeling exon 51 skipping (mean [SD], approximately 159%
[46.3%] of control) (P < .001) (Figure 2). We did not identify a
relationship between the levels of dystrophin and utrophin.
Patient 3 with IMD had among the highest sarcolemmal dys-
trophin and utrophin levels (mean [SD], approximately 41%
[10.7%] with MANDYS106 and 540% [202.3%] of control, re-
spectively); however, a similar level of dystrophin expression
in patient 6with IMD (mean [SD], approximately 48% [20.1%]
of control) was accompanied by a lower level of sarcolemmal
utrophin (mean [SD], approximately 182% [100.5%] of con-
trol) (Figure 1 and eFigure 3 in Supplement).
We found no obvious difference in themean or spread of
dystrophin or dystrophin-associated protein expression be-
tweenpatientswithBMDofdifferent severities (eFigure 1 and
eFigure 3 in Supplement). We previously demonstrated that
the levels of dystrophin and somedystrophin-associatedpro-
teinsare correlatedwithclinical severity inaBMDcohortmim-
icking exon 51 skipping.21 Herein, we found no clear correla-
tion between dystrophin, β-dystroglycan, nNOS, or utrophin
proteinexpressionandclinical severity for themodel45group.
Asymptomatic patients, thosewithmildBMD, and thosewith
severe BMD have comparable dystrophin and dystrophin-
associated protein levels (Figure 3).
Discussion
Wehavequantitatively assessed the levels of dystrophin tran-
script and protein in a cohort of 21 patients with IF and OOF
deletions around exons 44 and 45. We compared these data
with our previous study21 to provide the most comprehen-
sive characterization of patients with BMD mimicking exon
skipping todate.Ourdata provide a robust baseline for the as-
sessment of dystrophin transcript and protein levels in boys
with DMD recruited into future clinical trials.
Patients in the model 44/45 OOF group had higher levels
of dystrophin protein than thosemodeling exon 51 or 53 skip-
ping.We attribute this to a higher level of revertant and trace
dystrophin expression in patients in the model 44/45 OOF
group.22,39Exon44skips spontaneouslywhensurroundingex-
ons are deleted40; patientswith these “leaky”mutations pre-
Figure 2. Comparative Immunohistochemical Analysis of Dystrophin-Associated Protein Expression in PatientsWith In-Frame or Out-of-FrameDMD
Deletions Around Exons 44 and 45
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Transverse muscle sections were immunolabeled for β-spectrin, β-dystroglycan,
neuronal nitric oxide synthase (nNOS), and utrophin. Expression was quantified
relative to control muscle in 40muscle fibers and normalized to β-spectrin
expression. Patients were grouped according to corresponding exon skipping
models for Duchennemuscular dystrophy: control, exon 44 or 45 skippable
out-of-frame (OOF) deletions (model 44 OOF andmodel 45 OOF), and in-frame
(IF) deletions mimicking exon 45 skipping (model 45 IF). Data are presented as
mean (SD) of the difference between sample means. Dotted lines indicate the
mean dystrophin-associated protein expression level from patients with Becker
muscular dystrophy who have IF (blue lines) and OOF (gray lines) deletions
modeling exon 51 skipping.21
aP = .01.
bP < .001.
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sentwithunpredictablephenotypes,whichhighlights the limi-
tation of an exclusively genetic diagnosis and the value of
accuratemuscle pathology. Indeed, 4 of 9 patients in ourOOF
cohort had IMD or BMD phenotypes instead of the expected
DMDphenotype.This is in stark contrast toOOFdeletions fur-
ther 3′ aroundexon51,whichpredictably present asDMD.21,41
Although in vitro data suggest that patients with leakymuta-
tions might be ideal candidates for exon skipping,39 the con-
sequences of the higher background levels of dystrophin and
the lower level of dystrophinprotein restoration that couldbe
achievedbyexon skipping in thesepatients areunknown.The
efficacy and efficiency of exon 44 and45AOswill thus be dif-
ficult to measure without pretreatment biopsies and sensi-
tive quantitativemethods. Phase I and II clinical trials of exon
44 and 45 AOs are under way (ClinicalTrials.gov identifiers
NCT01037309 andNCT01826474, respectively); in light of the
discusseddata, patientswithdifferent treatment responses in
these trials are likely. The higher level of dystrophin expres-
sion in patients eligible for exon 44 or 45 trials may influence
their immunity todystrophin.42 Immunity to self- andnonself-
dystrophinepitopes requires further investigationand should
be assessed in future DMD clinical trials.
In our study, recruitment may be biased toward patients
with severe BMD as many patients with asymptomatic BMD
pass undiagnosed. On this note, we could not recruit any pa-
tientswithBMDwhohavedeletionsmimicking exon44 skip-
ping; thus, our cohort cannot represent the full spectrum of
deletions in this area, some of which have never been re-
ported.Nevertheless, allpatientswith IFdeletions in this study
had dystrophin protein levels approximately 40% of control
and 9 of 12 patients hadmild BMD orwere asymptomatic. Al-
though our sample size is too small for meaningful analysis,
weconsideredourpreviouscohortof IFdeletionsaroundexon
51 less severe (and the dystrophin proteinmore stable and/or
Figure 3. Correlation of Dystrophin and Dystrophin-Associated Protein ExpressionWith Clinical Severity in
PatientsWith In-FrameDMDDeletions Around Exons 44 and 45
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functional) as only 1 of 17 patients had severe BMD,while 4 of
17 were asymptomatic.21
While a number of disease modifiers have been identi-
fied forDMD,43,44 no information is available onwhether they
contribute to BMD variability. Variability in BMD is likely af-
fected by the structure and stability of dystrophin. Our 12 pa-
tients with BMD maintain an intact hinge 3, which results in
more variable BMD phenotypes.45 The phasing of helical re-
peats in patientswith deletions in exons 45 to 47 and 45 to 49
is disrupted46; in our study, there are patients with asymp-
tomatic, mild, and severe BMDwith out-of-phase repeats.
Weobservednoclear correlationbetween the level of dys-
trophin transcript or protein expressionwith clinical severity
in patientswith IF deletionsmodeling exon 45 skipping. This
is in concordance with recently presented protein data on 13
patients with BMDwho have a deletion of exons 45 to 47.47
Antisense oligonucleotide–mediated exon skipping relies
on the availability of the dystrophin transcript. Our finding
that patientswith IF andOOF deletions have 5′DMD transcript
expression levels comparable to control is supported by stud-
ies suggesting that transcript stability rather than amount is
important for high levels of dystrophin protein expression.35,48
We show that all 12 patientswith IF deletions had a stable tran-
script, while all patients with an OOF deletion (accompanied
by a low level of dystrophin expression) had an unstable dys-
trophin transcript. This is supported by another study that
showed a 5′ to 3′ increase in threshold cycle values in patients
with DMD who have OOF deletions and point mutations.49
Taken together, these data highlight the need for careful con-
sideration of the location of primers and probes when quanti-
fying dystrophin mRNA and suggest that transcript stability
correlates with protein production better than overall tran-
script levels. Whether exon skipping restores the stability of
thedystrophin transcript invivoandhowexistingpatient tran-
script instabilities (whichmay vary according to theOOFmu-
tation) affect theoutcomeof exonskipping remain tobedeter-
mined. The assessment of DMD transcript stability could be
exploredas amarker of response to therapy.Recentdata show
that the transcript imbalance ismorepronounced inmdxmice
harboringanonsensemutationvswild type.35Thus, a strategy
to restore andmaintainDMD transcript stabilitymay improve
the efficiency of AO-mediated exon skipping.
In summary, our data suggest that, as with exon 51,
AO-mediatedexonskippingof exon44or45mayprovebenefi-
cial to patients with DMD, as patients with IF mutations in
this region had a predominantly mild BMD phenotype. How-
ever, we highlight that the skipping of different exons will
likely yield different levels of dystrophin protein restoration
as well as dystrophin proteins that differ in their stability and
functionality.
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